Colleen  Tupper net worth and biography

Colleen Tupper Biography and Net Worth

Colleen Tupper joined Collegium Pharmaceutical in May 2021 as Executive Vice President and Chief Financial Officer. Prior to joining Collegium, Colleen most recently served as Chief Financial Officer, U.S. Business Unit as well as a member of the U.S. Business Unit Executive Leadership Team and the Global Finance Leadership Team at Takeda. Prior to that role, Ms. Tupper held several roles of increasing responsibility at Shire Pharmaceuticals (acquired by Takeda in 2019) including Vice President, U.S. Commercial Finance; Vice President, Finance Integration Lead; and Vice President, Head of Finance Global Neuroscience and Ophthalmics. Earlier in her career, Ms. Tupper served in various finance and accounting roles at both Shire Pharmaceuticals and Antigenics (now Agenus). Ms. Tupper received a B.S. in Accounting from Franklin Pierce University.

What is Colleen Tupper's net worth?

The estimated net worth of Colleen Tupper is at least $6.01 million as of November 6th, 2025. Tupper owns 126,667 shares of Collegium Pharmaceutical stock worth more than $6,007,816 as of December 5th. This net worth estimate does not reflect any other investments that Tupper may own. Additionally, Tupper receives an annual salary of $848,290.00 as CFO at Collegium Pharmaceutical. Learn More about Colleen Tupper's net worth.

How old is Colleen Tupper?

Tupper is currently 48 years old. There are 5 older executives and no younger executives at Collegium Pharmaceutical. The oldest executive at Collegium Pharmaceutical is Dr. Thomas B. Smith FAAFP, M.D., Executive VP & Chief Medical Officer, who is 63 years old. Learn More on Colleen Tupper's age.

What is Colleen Tupper's salary?

As the CFO of Collegium Pharmaceutical, Inc., Tupper earns $848,290.00 per year. The highest earning executive at Collegium Pharmaceutical is Mr. Joseph J. Ciaffoni, President, CEO & Director, who commands a salary of $1,690,000.00 per year. Learn More on Colleen Tupper's salary.

How do I contact Colleen Tupper?

The corporate mailing address for Tupper and other Collegium Pharmaceutical executives is 100 Technology Center Drive, Stoughton MA, 02072. Collegium Pharmaceutical can also be reached via phone at (781) 713-3699 and via email at [email protected]. Learn More on Colleen Tupper's contact information.

Has Colleen Tupper been buying or selling shares of Collegium Pharmaceutical?

In the last ninety days, Colleen Tupper has sold $1,215,900.00 in Collegium Pharmaceutical stock. Most recently, Colleen Tupper sold 30,000 shares of the business's stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $40.53, for a transaction totalling $1,215,900.00. Following the completion of the sale, the chief financial officer now directly owns 126,667 shares of the company's stock, valued at $5,133,813.51. Learn More on Colleen Tupper's trading history.

Who are Collegium Pharmaceutical's active insiders?

Collegium Pharmaceutical's insider roster includes Garen Bohlin (Director), Joseph Ciaffoni (CEO), Joseph Ciaffoni (Pres), Scott Dreyer (EVP), John Freund (Director), Michael Heffernan (Director), Shirley Kuhlmann (EVP), Thomas Smith (EVP), Colleen Tupper (CFO), and Colleen Tupper (Exec. VP & CFO ). Learn More on Collegium Pharmaceutical's active insiders.

Are insiders buying or selling shares of Collegium Pharmaceutical?

During the last year, insiders at the specialty pharmaceutical company sold shares 14 times. They sold a total of 201,586 shares worth more than $6,745,824.04. The most recent insider tranaction occured on November, 6th when CFO Colleen Tupper sold 30,000 shares worth more than $1,215,900.00. Insiders at Collegium Pharmaceutical own 2.5% of the company. Learn More about insider trades at Collegium Pharmaceutical.

Information on this page was last updated on 11/6/2025.

Colleen Tupper Insider Trading History at Collegium Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2025Sell30,000$40.53$1,215,900.00126,667View SEC Filing Icon  
3/14/2025Sell977$30.00$29,310.00164,269View SEC Filing Icon  
3/11/2025Sell10,445$30.01$313,454.45165,246View SEC Filing Icon  
3/6/2025Sell1,949$30.00$58,470.00177,195View SEC Filing Icon  
5/28/2024Sell19,710$34.21$674,279.10130,845View SEC Filing Icon  
3/15/2023Sell31,640$23.77$752,082.80105,420View SEC Filing Icon  
10/4/2022Sell4,350$17.35$75,472.5090,304View SEC Filing Icon  
See Full Table

Colleen Tupper Buying and Selling Activity at Collegium Pharmaceutical

This chart shows Colleen Tupper's buying and selling at Collegium Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Collegium Pharmaceutical Company Overview

Collegium Pharmaceutical logo
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Read More

Today's Range

Now: $47.43
Low: $47.00
High: $47.74

50 Day Range

MA: $39.09
Low: $32.04
High: $47.85

2 Week Range

Now: $47.43
Low: $23.23
High: $48.37

Volume

270,066 shs

Average Volume

654,743 shs

Market Capitalization

$1.50 billion

P/E Ratio

29.46

Dividend Yield

N/A

Beta

0.61